1,962 results match your criteria Primary CNS Lymphoma


Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China.

Chin J Cancer Res 2019 Feb;31(1):152-161

Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Objective: To explore the clinicobiologic features and outcomes of diffuse large B-cell lymphoma (DLBCL) patients in China according to the primary site.

Methods: A total of 1,085 patients diagnosed with DLBCL in National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College during a 6-year period were enrolled. Their clinical characteristics and outcomes were analyzed according to the primary site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21147/j.issn.1000-9604.2019.01.10DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433587PMC
February 2019
2 Reads

Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Acta Oncol 2019 Apr 17:1-10. Epub 2019 Apr 17.

a Institute of Neurology , Medical University of Vienna , Vienna , Austria.

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups.

Material And Methods: Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1599137DOI Listing

X-Linked Lymphoproliferative Syndrome Presenting as Adult-Onset Multi-Infarct Dementia.

J Neuropathol Exp Neurol 2019 May;78(5):460-466

Department of Neurology, Mayo Clinic, Jacksonville, Florida.

Pathogenic hemizygous variants in the SH2D1A gene cause X-linked lymphoproliferative (XLP) syndrome, a rare primary immunodeficiency usually associated with fatal Epstein-Barr virus infection. Disease onset is typically in early childhood, and the average life expectancy of affected males is ∼11 years. We describe clinical, radiographic, neuropathologic, and genetic features of a 49-year-old man presenting with central nervous system vasculitis that was reminiscent of adult primary angiitis but which was unresponsive to treatment. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/jnen/article/78/5/460/5445919
Publisher Site
http://dx.doi.org/10.1093/jnen/nlz018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467195PMC
May 2019
3 Reads

Focal Intramedullary Spinal Cord Lesion in HIV/AIDs: Toxoplasmosis vs. Lymphoma.

World Neurosurg 2019 Apr 11. Epub 2019 Apr 11.

Department of Neurosurgery, Santa Clara Valley Medical Center, San Jose, CA 95128; Department of Neurosurgery, Stanford University School of Medicine, Stanford, CA 94305. Electronic address:

Background: Neurological complications are common in HIV/AIDS patients. While both the central nervous system (CNS) and the peripheral nervous system (PNS) can be affected, up to 80% of HIV/AIDS patients have CNS involvement during the course of their illness. The brain is the primary site of HIV/AIDS associated CNS complications. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18788750193104
Publisher Site
http://dx.doi.org/10.1016/j.wneu.2019.04.057DOI Listing
April 2019
3 Reads

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Lancet Respir Med 2019 Apr 10. Epub 2019 Apr 10.

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. Electronic address:

Background: Anaplastic lymphoma kinase-positive (ALK-positive) disease occurs in approximately 5% of all patients with non-small-cell lung cancer, with a similar incidence reported in Asian patients. This study is the first phase 3 randomised trial recruiting only Asian patients to compare alectinib with crizotinib as a first-line treatment for ALK-positive non-small-cell lung cancer with 600 mg of alectinib twice per day. This study assessed consistency of the progression-free survival benefit with the global phase 3 ALEX study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2213-2600(19)30053-0DOI Listing
April 2019
1 Read

Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential.

Insights Imaging 2019 Apr 11;10(1):46. Epub 2019 Apr 11.

Oncology, University of Nebraska Medical Center, 986840 Nebraska Medical Center, Omaha, NE, 68198-6840, USA.

Objective: Central nervous system post-transplant lymphoproliferative disorder (CNS-PTLD) is a rare disease that presents with non-specific signs and symptoms. The purpose of this article is to present the imaging appearances of CNS-PTLD by magnetic resonance imaging. We highlight the differential diagnostic considerations including primary central nervous system lymphoma, glioblastoma, cerebral abscess, and metastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13244-019-0726-6DOI Listing
April 2019
1 Read

Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplant-Eligible Patients.

Biol Blood Marrow Transplant 2019 Apr 6. Epub 2019 Apr 6.

Departments of Oncology and Medicine, University of Calgary, Alberta.

While no widely accepted standard treatment regimen exists for primary CNS lymphoma (PCNSL), growing evidence supports one that incorporates autologous stem cell transplant (ASCT) as consolidative therapy when feasible. In November 2011, the Alberta Hematology Tumor Team established a new clinical practice guideline (CPG) for PCNSL involving high dose methotrexate (HDMTX)/cytarabine-based induction followed by ASCT for eligible patients using a thiotepa and busulfan (TBu) conditioning regimen that omitted cyclophosphamide from the regimen that was used prior to 2011. This retrospective study analyzed all 64 PCNSL patients consecutively diagnosed in three Canadian centers between November 2011 and December 2017 to evaluate adherence to the 2011 CPG and associated outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2019.04.004DOI Listing
April 2019
1 Read

Differential Diagnostic Value of Texture Feature Analysis of Magnetic Resonance T2 Weighted Imaging between Glioblastoma and Primary Central Neural System Lymphoma.

Chin Med Sci J 2019 Mar;34(1):10-17

Department of Radiology, Hainan Hospital of Chinese PLA General Hospital, Sanya, Hainan 572013, China.

Objective To investigate the difference in tumor conventional imaging findings and texture features on T2 weighted images between glioblastoma and primary central neural system (CNS) lymphoma.Methods The pre-operative MRI data of 81 patients with glioblastoma and 28 patients with primary CNS lymphoma admitted to the Chinese PLA General Hospital and Hainan Hospital of Chinese PLA General Hospital were retrospectively collected. All patients underwent plain MR imaging and enhanced T1 weighted imaging to visualize imaging features of lesions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24920/003548DOI Listing
March 2019
1 Read

Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma.

Leuk Lymphoma 2019 Apr 3:1-8. Epub 2019 Apr 3.

c BC Cancer Centre for Lymphoid Cancer and University of British Columbia , Vancouver , BC , Canada.

In this study, we analyzed the evolution of the prognosis of primary central nervous system lymphoma (PCNSL) patients as they reach selected progression-free survival (PFS) milestones after high-dose methotrexate (HD-MTX)-based therapy. In total, 258 and 146 patients were included from Denmark and British Columbia, respectively. All patients were diagnosed during 2000-2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1594219DOI Listing
April 2019
4 Reads

Primary vitreoretinal lymphoma.

Saudi J Ophthalmol 2019 Jan-Mar;33(1):66-80. Epub 2019 Jan 14.

Department of Ophthalmology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece.

Primary vitreoretinal lymphoma (PVRL) is a rare ocular lymphoid malignancy, which consists a subset of primary central system lymphoma (PCNSL) and the most common type of intraocular lymphoma. The involvement of eyes is estimated to be approximately 20% of PCNSL, but the brain involvement may be up to 80% of PVRL. Typically, PVRL is a high grade B-cell malignancy of the retina and needs to be assorted from choroidal low-grade B-cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sjopt.2018.12.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424706PMC
January 2019
2 Reads

Lymphoma of the optic apparatus in an Immunocompetent Patient: A Case Report and Review of the Literature.

World Neurosurg 2019 Mar 28. Epub 2019 Mar 28.

Tulane Medical Center, Department of Neurosurgery, New Orleans, LA, USA. Electronic address:

Primary optic apparatus involvement by lymphoma is an exceedingly rare entity, with only three cases previously reported in the literature. Whether this represents a distinct pathology, metastatic disease from an unidentified systemic lymphoma, or the first manifestation of evolving primary central nervous system lymphoma (PCNSL) is not currently understood. We present a case of a young immunocompetent male with rapidly progressive visual loss who was found to have isolated lymphomatous involvement of the optic apparatus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2019.03.224DOI Listing
March 2019
1 Read
2.417 Impact Factor

Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients.

BMC Cancer 2019 Mar 29;19(1):287. Epub 2019 Mar 29.

Clinic of Hematology, Oncology and Palliative Care, Klinikum Stuttgart, Stuttgart, Germany.

Background: Primary central nervous system lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the central nervous system (CNS) with rising incidence among patients > 65 years. Although elderly patients are able to tolerate aggressive systemic chemotherapy, previous studies have demonstrated inferior outcomes for patients who present with a poor performance status (PS) and older age. Usually, intensive treatment approaches including high-dose chemotherapy followed by autologous stem cell transplantation (HDT-ASCT) are only offered to patients younger than 65-70 years of age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5473-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440161PMC
March 2019
6 Reads

Central Nervous System Involvement of Natural Killer and T Cell Neoplasms.

Curr Oncol Rep 2019 Mar 27;21(5):40. Epub 2019 Mar 27.

Department of Neurology, Indiana University Health, Indiana University School of Medicine, 355 W. 16th St., Ste 3200, Indianapolis, IN, 46202, USA.

Purpose Of Review: Peripheral natural killer (NK) and T cell neoplasms comprise approximately 10-15% of non-Hodgkin lymphomas. There are 27 different subtypes of peripheral NK and T cell neoplasms, each of which is relatively uncommon. Treatment has been largely extrapolated from case series, retrospective reports, and paradigms developed for the aggressive B cell lymphomas. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0794-2
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0794-2DOI Listing
March 2019
2 Reads

Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature.

Clin Lymphoma Myeloma Leuk 2019 Feb 26. Epub 2019 Feb 26.

Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL. Electronic address:

Background: Central nervous system (CNS) lymphoma is associated with poor outcomes. Autologous stem cell transplantation (ASCT) has been reported to improve outcomes when used as a consolidation strategy in primary CNS lymphoma (PCNSL) and as a salvage strategy in patients with disease relapse limited to the CNS. Herein, we describe our experience of using ASCT in PCNSL and secondary CNS lymphoma (SCNSL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.02.013DOI Listing
February 2019
2 Reads

Seizures in patents with primary central nervous system lymphoma: Prevalence and associated features.

J Neurol Sci 2019 May 14;400:34-38. Epub 2019 Mar 14.

Department of Neurology, Medical University of South Carolina, Charleston, SC, USA.

Objective: Primary central nervous system (CNS) lymphoma (PCNSL) is a rare, aggressive, yet highly chemosensitive form of non-Hodgkin lymphoma which is associated with significant morbidity. Very little is known about the long-term risk for and features of seizures associated with this condition.

Methods: We performed a retrospective and longitudinal analysis of 36 patients with pathologically and radiographically confirmed primary CNS lymphoma to evaluate the incidence, prevalence and features associated with seizures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.03.011DOI Listing
May 2019
2 Reads

Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis.

Acta Neuropathol Commun 2019 Mar 18;7(1):43. Epub 2019 Mar 18.

Laboratoire d'Hématologie- Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Hôpital E. Muller, 20 avenue de Dr Laennec, 68100, Mulhouse, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-019-0692-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421652PMC

Primary Cutaneous Diffuse Large B-Cell Lymphoma of the Upper Limb: Double Hit/Double Expressor with CNS Involvement: From Hospice to Remission.

Case Rep Hematol 2019 7;2019:3953470. Epub 2019 Feb 7.

Methodist Hospital, Texas Transplant Institute, San Antonio, Texas, USA.

We report a patient with diffuse large B-cell lymphoma of skin, nongerminal center type double hit double expressor, with an initial presentation as a left forearm mass. The patient underwent chemotherapy after initial diagnosis. After chemotherapy regimen, she developed a second mass, followed by CNS involvement with neurological defects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/3953470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383425PMC
February 2019
1 Read

Primary central nervous system plasmablastic lymphoma in an HIV-positive patient.

BMJ Case Rep 2019 Mar 14;12(3). Epub 2019 Mar 14.

Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Plasmablastic lymphoma (PBL) is a rare subtype of diffuse large B-cell lymphoma, highly associated with HIV and Epstein-Barr virus (EBV) infections. It commonly presents in extranodal sites, often an oral mass, but reports of primary central nervous system PBL (PCNSPBL) are exceedingly rare. Here, we report on a 33-year-old man with newly diagnosed HIV infection who presented with acute-onset unilateral visual disturbance and was found to have biopsy-proven PCNSPBL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bcr-2018-226755DOI Listing
March 2019
1 Read

Primary vitreoretinal lymphoma: prevalence, impact, and management challenges.

Clin Ophthalmol 2019 14;13:353-364. Epub 2019 Feb 14.

Department of Retina and Vitreous, Narayana Nethralaya, Bengaluru - 560010, India,

Primary vitreoretinal lymphoma (PVRL) is a rare and potentially fatal intraocular malignancy. More than half of PVRL cases eventually involve the central nervous system (CNS). PVRL frequently masquerades as chronic uveitis. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/primary-vitreoretinal-lymphoma-pre
Publisher Site
http://dx.doi.org/10.2147/OPTH.S159014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387616PMC
February 2019
12 Reads

[Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab].

Rinsho Ketsueki 2019;60(2):87-92

Division of Clinical Oncology/Hematology, Department of Internal Medicine, The Jikei University School of Medicine.

Primary central nervous system lymphoma (PCNSL) is a rare, aggressive type of non-Hodgkin lymphoma with a poor prognosis and no defined optimal therapeutic strategies. We retrospectively analyzed the survival of six PCNSL patients who were treated with high-dose methotrexate (HDMTX) -based chemotherapy combined with rituximab. The median age at diagnosis was 71 (range, 54-75) years, and the ECOG performance status was ≥3 in four patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11406/rinketsu.60.87DOI Listing
January 2019
1 Read

Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences.

J Glob Oncol 2019 Feb;5:1-9

1 Dr B.R.A. Institute Rotary Cancer Hospital, New Delhi, India.

Purpose: The information about the outcome of primary CNS lymphoma (PCNSL) in India is scarce, because there is no population-based or large hospital-based data.

Materials And Methods: This is a retrospective study that spanned 17 years (2001 to 2017) to study the outcome of PCNSL at the All India Institute of Medical Sciences (AIIMS), which is a tertiary care center in Northern India.

Results: Only one of 99 patients was positive for HIV serology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.18.00124DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426510PMC
February 2019
3 Reads

Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study.

Lancet Oncol 2019 Apr 21;20(4):531-545. Epub 2019 Feb 21.

Centre for Childhood Cancer Survivor Studies, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. Electronic address:

Background: Few studies have investigated the risks of subsequent primary neoplasms after adolescent and young adult (AYA) cancer. We investigated the risks of specific subsequent primary neoplasms after each of 16 types of AYA cancer.

Methods: The Teenage and Young Adult Cancer Survivor Study is a population-based cohort of 200 945 survivors of cancer diagnosed when aged 15-39 years in England and Wales from Jan 1, 1971, to Dec 31, 2006. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30903-3DOI Listing
April 2019
1 Read

Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study.

J Clin Oncol 2019 Apr 20;37(10):823-833. Epub 2019 Feb 20.

3 Institut Curie, Site Saint-Cloud, Saint-Cloud, France.

Purpose: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL).

Patients And Methods: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m day (D) 1, methotrexate 3 g/m D1; D15, VP16 100 mg/m D2, BCNU 100 mg/m D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m D1, cytarabine 3 g/m D1 to D2). Intensive chemotherapy consisted of thiotepa (250 mg/m/d D9; D8; D7), busulfan (8 mg/kg D6 through D4), and cyclophosphamide (60 mg/kg/d D3; D2). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.18.00306DOI Listing
April 2019
9 Reads
18.428 Impact Factor

Primary CNS Lymphoma in the Elderly: The Challenge.

Acta Haematol 2019 15;141(3):138-145. Epub 2019 Feb 15.

Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.

Primary central nervous system (CNS) lymphoma is an aggressive brain tumor sensitive to chemotherapy and radiotherapy. Its incidence has increased in the elderly, and they account for the majority of patients. The median survival of patients older than 70 years did not change over the last 40 years and remained in the range of 6-7 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495284DOI Listing
February 2019

Long-Term Evaluation of Combination Treatment of Single Agent HD-MTX Chemotherapy up to Three Cycles and Moderate Dose Whole Brain Irradiation for Primary CNS Lymphoma.

J Chemother 2019 Feb;31(1):35-41

b Department of Radiation Medicine , Hokkaido University Faculty of Medicine , Sapporo , Japan.

High-dose methotrexate (HD-MTX)-based chemotherapy in combination with whole brain radiotherapy (WBRT) has been a common therapy for primary central nervous system lymphoma (PCNSL). The aim of this study was to evaluate the survival benefit of a minimized cycle of HD-MTX monotherapy prior to WBRT. A maximum of three cycles of HD-MTX was combined with a WBRT dose of 30 Gy and an additional localized boost was administered where remnant was observed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1120009X.2018.1546984DOI Listing
February 2019
5 Reads

[Central Neurological Diagnosis in Patients Infected with HIV in the Infectious Diseases Unit of University Hospital of Casablanca, Morocco].

Bull Soc Pathol Exot 2018 ;111(1):24-30

Service des maladies infectieuses, CHU de Ibn Rochd, Casablanca, Maroc.

The aim of this work is to study the epidemiology of central neurological system (CNS) diagnosed in the population of people living with HIV in the department of infectious diseases in UHC Ibn Rochd of Casablanca from January 2005 to May 2015. The demographic and clinical profile along with the outcome of these patients were studied. The data were collected from Nadis software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3166/bspe-2018-0004DOI Listing
January 2018
1 Read

Central Nervous System Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.

Cureus 2018 Nov 30;10(11):e3660. Epub 2018 Nov 30.

Neurosurgery, Stanford University School of Medicine, Stanford, USA.

Chronic lymphocytic leukemia (CLL) is the most common type of leukemia that affects older adults in the Western world. Symptomatic nervous system invasion in undiagnosed CLL is rare, poorly understood, challenging to treat, and associated with decreased survival. The average survival of CLL patients with central nervous system (CNS) involvement is 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364951PMC
November 2018
1 Read

Diffuse large B-cell lymphoma of the central nervous system presenting as "lymphomatosis cerebri" and dementia in elderly man: Case report and review of the literature.

Medicine (Baltimore) 2019 Feb;98(6):e14367

Department of Hematology, Hospital Israelita Albert Einstein.

Rationale: Lymphomatosis cerebri is a rare form of PCNSL, characterized by diffuse infiltration of lymphoma cells in cerebral parenchyma, without mass-formation and mild or no contrast enhancement on magnetic resonance (MR) imaging. There are less than 50 cases described in the literature under the term Lymphomatosis cerebri.

Patient Concerns: A 74-year-old man presented to our service with progressive dementia for 12 months and accelerated cognitive decline within the last two months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000014367DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6380721PMC
February 2019
3 Reads

miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.

Pathol Oncol Res 2019 Feb 2. Epub 2019 Feb 2.

Department of Neurosurgery, Hangzhou Xiasha Hospital, Sir Run Run Shaw Hospital, Medical College, Zhejiang University, Hangzhou, 310016, People's Republic of China.

Primary central nervous system lymphoma (PCNSL) is an aggressive and rare subtype of non-Hodgkin lymphoma, arising exclusively in the CNS with a poor prognosis. Previous evidence has proved that MGMT was a promising target involving in TMZ resistance of PCNSL. Our study described a new miR-370-mediated mechanism of MGMT regulation in PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12253-019-00605-4DOI Listing
February 2019
4 Reads
1.806 Impact Factor

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial.

Lancet Haematol 2019 Feb;6(2):e100-e109

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.

Methods: We did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23523026183021
Publisher Site
http://dx.doi.org/10.1016/S2352-3026(18)30216-3DOI Listing
February 2019
16 Reads

Lenalidomide in Combination with Intravenous Rituximab (REVRI) in Relapsed/Refractory Primary CNS Lymphoma or Primary Intraocular Lymphoma: a Multicenter Prospective "Proof of Concept" Phase II Study of the French Oculo-Cerebral Lymphoma (LOC) Network and the Lymphoma Study Association (LYSA).

Ann Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Hematology, Institut Curie, Site Saint-Cloud, France.

Background: Primary central nervous system lymphomas (PCNSLs) are mainly diffuse large B-cell lymphomas (DLBCLs) of the non-germinal center B-cell (non-GCB) subtype. This study aimed to determine the efficacy of rituximab plus lenalidomide (R2) in DLBCL-PCNSL.

Patients And Methods: Patients with refractory/relapsed (R/R) DLBCL-PCNSL or primary vitreoretinal lymphoma (PVRL) were included in this prospective phase II study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/annonc/mdz032DOI Listing
January 2019
11 Reads

Primary central nervous system Hodgkin Lymphoma: A case discussion and a hypothesis on the etiology.

Avicenna J Med 2019 Jan-Mar;9(1):28-31

Hematogenix Laboratory Services, Tinley Park, IL, USA.

Hodgkin Lymphoma (HL) is a systemic disease with involvement of the cervical, supraclavicular, and mediastinal lymph nodes. It is commonly diagnosed in patients within the second and third decades of their lives. Diagnosis is usually made based on the distinct morphological and immunohistochemical characteristics, with the tissue biopsy being the cornerstone of workup. Read More

View Article

Download full-text PDF

Source
http://www.avicennajmed.com/preprintarticle.asp?id=240257
Publisher Site
http://dx.doi.org/10.4103/ajm.AJM_104_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335883PMC
January 2019
13 Reads

ALK Inhibitors in the Treatment of ALK Positive NSCLC.

Front Oncol 2018 9;8:557. Epub 2019 Jan 9.

Department of Radiation Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China.

ALK inhibitors have shown positive advance in the treatment of ALK+ NSCLC. They have achieved better results in prolonging the progression free survival and improving quality of life in comparison to chemotherapy. We have assembled the evidence related to the efficacy and safety of these agents in the treatment of ALK positive NSCLC. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fonc.2018.00557/
Publisher Site
http://dx.doi.org/10.3389/fonc.2018.00557DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333640PMC
January 2019
11 Reads

FGL2 promotes tumor progression in the CNS by suppressing CD103 dendritic cell differentiation.

Nat Commun 2019 01 25;10(1):448. Epub 2019 Jan 25.

Department of Pediatrics-Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Few studies implicate immunoregulatory gene expression in tumor cells in arbitrating brain tumor progression. Here we show that fibrinogen-like protein 2 (FGL2) is highly expressed in glioma stem cells and primary glioblastoma (GBM) cells. FGL2 knockout in tumor cells did not affect tumor-cell proliferation in vitro or tumor progression in immunodeficient mice but completely impaired GBM progression in immune-competent mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-08271-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6347641PMC
January 2019
4 Reads
10.742 Impact Factor

High-Dose Chemotherapy with Autologous Stem Cell Transplantation in Primary Central Nervous System Lymphoma: Data From the Japan Society for Hematopoietic Cell Transplantation Registry.

Biol Blood Marrow Transplant 2019 Jan 18. Epub 2019 Jan 18.

Department of Oncology/Hematology, Shimane University Hospital, Izumo, Japan.

High-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) has been shown to improve the prognosis of patients with central nervous system (CNS) lymphoma. We queried the Japan Society for Hematopoietic Cell Transplantation Registry for 2006 to 2015 to analyze the outcomes of 102 patients with primary CNS lymphoma (PCNSL) who underwent first HDT/ASCT. The median patient age was 54 years (range, 20 to 74 years), and 65 patients were treated in an upfront setting. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10838791193007
Publisher Site
http://dx.doi.org/10.1016/j.bbmt.2019.01.020DOI Listing
January 2019
19 Reads

Bilateral radiation therapy followed by methotrexate-based chemotherapy for primary vitreoretinal lymphoma.

Am J Hematol 2019 Apr 4;94(4):455-460. Epub 2019 Feb 4.

Department of Medicine, Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.

Primary vitreoretinal lymphoma (PVRL) is a subset of primary CNS lymphoma that presents as isolated ocular disease without brain involvement. Although ocular radiotherapy (RT) is an effective treatment for PVRL, the optimal treatment is uncertain. PVRL may later involve the brain in 56%-85% of patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25414DOI Listing
April 2019
3 Reads

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.

Lancet Oncol 2019 Feb 7;20(2):216-228. Epub 2019 Jan 7.

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.

Background: The prognosis for primary CNS lymphoma has improved with the use of high-dose methotrexate-based chemotherapy, but patient outcomes remain poor. Rituximab, a chimeric monoclonal antibody that targets the CD20 cell surface protein, has substantial activity in systemic CD20-positive diffuse large B-cell lymphoma, but its efficacy in primary CNS lymphoma is unknown and low penetration of the large rituximab molecule through the blood-brain barrier could limit its effect. We aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183074
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30747-2DOI Listing
February 2019
20 Reads

Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions.

Leuk Lymphoma 2019 Jan 10:1-5. Epub 2019 Jan 10.

a Department of Neurology , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Lymphomatous brain lesions can represent primary central nervous system (CNS) lymphoma or secondary involvement as part of systemic disease (SCNSL). In this study, we characterize staging evaluations in a large patient cohort with newly-diagnosed brain lymphomas, to determine the frequency of SCNSL and secondary malignancies. This retrospective review includes 262 patients with newly-diagnosed lymphomatous CNS lesions evaluated at Memorial Sloan Kettering Cancer Center between 2006 and 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1563294DOI Listing
January 2019
9 Reads

Central Nervous System Peripheral T Cell Lymphoma Manifesting as Lymphomatosis Cerebri That Was Misdiagnosed as Neuro-Behçet's Disease: A Case Report.

Case Rep Oncol 2018 Sep-Dec;11(3):806-813. Epub 2018 Nov 29.

Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan.

Background: Lymphomatosis cerebri (LC) is a unique form of primary central nerves lymphoma (PCNSL), which presents as diffuse infiltration of lymphoma cells characteristically in the white matter rather than tumor formation. However, the involvement of central nervous system (CNS) is unclear because of the lack of contrast enhancement.

Case Presentation: We treated a 53-year-old woman with LC and brain lesions resembling neuro-Behcet's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000495033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323408PMC
November 2018
14 Reads

Post-transplant primary central nervous system lymphoma after Epstein-Barr virus cerebellitis.

J Neurovirol 2019 Jan 3. Epub 2019 Jan 3.

Division of Neurology, Mayo Clinic Arizona, 13400 East Shea Boulevard, Scottsdale, AZ, 85259, USA.

Post-transplantation lymphoproliferative disorder (PTLD) is a complication of solid organ and hematopoietic stem cell transplantation. Cases with isolated central nervous system (CNS) disease are rare. Epstein-Barr virus (EBV) plays a causative role. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13365-018-0711-8DOI Listing
January 2019
3 Reads

Cultured Cells Isolated from CNS Indolent B-Cell Lymphoma Have Characteristics of Mesenchymal Stem Cells: A Clinical Case and Scientific Research.

Int J Hematol Oncol Stem Cell Res 2018 Jul;12(3):169-174

Laboratory of Clinical Immunology, University Hospital "St. Ivan Rilski", Department of Clinical Laboratory and Clinical Immunology, Medical University of Sofia, Sofia, Bulgaria.

The case report presented here describes the culturing and characterization of mesenchymal stem cells (MSCs) isolated from a primary indolent B-cell lymphoma, located in the CNS of an immunocompetent patient. The presence of such cells in the tumor mass can further elucidate the pathogenesis of the disease and reveal possible future approaches for its treatment. We present a case report of a 61-year-old immunocompetent woman who had an episode of confusion with numbness in the right leg and the right arm, slurred and dysarthric speech and urine incontinence. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305270PMC
July 2018
4 Reads

Solitary Primary Central Nervous System Lymphoma Mimicking Third Ventricular Colloid Cyst-Case Report and Review of Literature.

World Neurosurg 2019 Mar 19;123:286-294. Epub 2018 Dec 19.

Hamad Medical Corporate, Neurosurgery, Doha, Qatar.

Background: Primary central nervous system lymphoma is a rare malignant tumor of the central nervous system. It is associated with poor prognosis and accounts for 0.7%-0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.12.026DOI Listing
March 2019
2 Reads

CSF TACI and BAFF levels in patients with primary CNS lymphoma as novel diagnostic biomarkers.

Ann Clin Transl Neurol 2018 Dec 19;5(12):1611-1616. Epub 2018 Oct 19.

Department of Neurology Graduate School of Medical Sciences Kumamoto University Kumamoto Japan.

We used an enzyme-linked immunosorbent assay to measure pretreatment B cell-activating factor belonging to the tumour necrosis factor family (BAFF) and transmembrane activator and CAML-interactor (TACI) levels in CSF and serum collected from patients with primary central nervous system lymphoma (PCNSL) and control groups. The decision tree analysis of CSF TACI and BAFF levels for patients with a PCNSL diagnosis showed 100% sensitivity and 100% specificity when we attempted to differentiate PCNSL from glioblastoma and CNS inflammatory diseases. The combination of CSF TACI and BAFF levels may thus be a novel and useful diagnostic biomarker of PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292192PMC
December 2018
3 Reads

AIDS-Associated Malignancies.

Cancer Treat Res 2019;177:1-21

Department of Dermatology, University of Texas Health Sciences Center at Houston, Houston, TX, 77030, USA.

Malignancies were one of the earliest recognized manifestations that led to the description of the acquired immune deficiency syndrome (AIDS). The majority of cancers in AIDS patients are associated with coinfection with oncogenic viruses, such as Epstein-Barr virus, human herpesvirus 8, and human papillomavirus, with resulting malignancies occurring secondary to diminished immune surveillance against viruses and virus-infected tumor cells. Over 50% of AIDS lymphomas are associated with Epstein-Barr virus (EBV) and/or HHV8 infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-03502-0_1DOI Listing
January 2019
8 Reads

Intrathecal Central Nervous System Prophylaxis in Patients With Diffuse Large B-cell Lymphoma at an Academic Healthcare System.

Clin Lymphoma Myeloma Leuk 2019 Feb 17;19(2):89-94. Epub 2018 Nov 17.

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute, Atlanta, GA.

Introduction: Intrathecal chemoprophylaxis is often administered to patients with diffuse large B-cell lymphoma (DLBCL) to lower the rates of central nervous system (CNS) relapse, although its benefit has not been well-described. Prognostic models, including the CNS-International Prognostic Index (IPI), have been developed to aid in identifying patients at highest risk for CNS relapse.

Patients And Methods: We evaluated 112 patients diagnosed with DLBCL from 2009 to 2016 at Emory Healthcare and classified them as high (n = 44) or low risk (n = 68) for CNS relapse and compared CNS prophylaxis rates and relapse rates between groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.014DOI Listing
February 2019

Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with leptomeningeal dissemination.

Semin Hematol 2018 10 6;55(4):179-181. Epub 2017 Jul 6.

Department of Biological Hematology, Pitie-Salpetriere Hospital, Paris, France; Centre de Recherche des Cordeliers, Cell Death and Drug Resistance in Lymphoproliferative Disorders, Paris, France.

We here report for the first time that low levels of interleukin (IL)-10 do not exclude lymphomatous meningitis (LM) in B-cell lymphoproliferative disorders (CLPD). Unexpectedly, IL-10 levels and IL-10:IL-6 ratio in CLPD differed from the levels observed in diffuse large B-cell lymphoma (DLBCL). We report the usefulness of adding the IL-10:IL-6 ratio in order to potentially reveal more aggressive lymphomas: either a transformation or an association with another "hidden" lymphoma such as primary CNS lymphoma (PCNSL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2017.06.005DOI Listing
October 2018
5 Reads

Primary CNS lymphoma patient-derived orthotopic xenograft model capture the biological and molecular characteristics of the disease.

Blood Cells Mol Dis 2019 03 16;75:1-10. Epub 2018 Nov 16.

Institut Curie, Site Saint-Cloud Hematology, Saint-Cloud, France. Electronic address:

Primary CNS lymphomas (PCNSL) are rare and poor prognosis diffuse large B-cell lymphomas. Because of the brain tumor environment and the restricted distribution of drugs in the CNS, specific PCNSL patient-derived orthotopic xenograft (PDOX) models are needed for preclinical research to improve the prognosis of PCNSL patients. PCNSL patient specimens (n = 6) were grafted in the caudate nucleus of immunodeficient nude mice with a 83% rate of success, while subcutaneous implantation in nude mice of human PCNSL sample did not generate lymphoma, supporting the role of the brain microenvironment in the PCNSL physiopathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcmd.2018.11.005DOI Listing
March 2019
3 Reads

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.

Lancet Haematol 2018 Dec;5(12):e609-e617

Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address:

Background: MYC gene rearrangement is present in approximately 10% of aggressive B-cell lymphomas, with half also harbouring a BCL2 gene rearrangement. Multiple retrospective studies of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone) have shown a worse outcome in patients with MYC rearrangement (alone or with rearrangement of BCL2 or BCL6, or both) than in patients without MYC rearrangement, and suggest improved outcomes after more intensive treatment. We aimed to determine the outcome of dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R), an intensive infusional treatment regimen, in untreated aggressive B-cell lymphoma with MYC rearrangement. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(18)30177-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6342507PMC
December 2018
5 Reads

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.

Am J Hematol 2019 Mar 5;94(3):291-298. Epub 2018 Dec 5.

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

Vitreoretinal lymphoma (VRL) management remains a challenge. We present 72 patients with VRL, diagnosed at Mayo Clinic between 1990-2018. Three nondiffuse large B-cell lymphoma (DLBCL) histology cases were excluded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25350DOI Listing
March 2019
3 Reads